Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

Sep 30, 2019

Scott T. Tagawa, MD, discusses data from the phase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer, presented at the ESMO Congress 2019.

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian/Weill Cornell Medical Center, discusses data from thephase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer, presented at the ESMO Congress 2019.

These data demonstrated that a cohort of patients with metastatic disease who had progressed on platinum-based regimens or immunotherapy experienced an overall response rate (ORR) of 29% with treatment of sacituzumab govitecan. These were heavily pretreated patients, who received an average of 4 prior lines of therapy, says Tagawa.

Related Content